WALTHAM, Mass.--(BUSINESS WIRE)--Cantai Therapeutics (“Cantai”) today announced its formation and the completion of a seed financing co-led by Agent Capital and 82VS (the affiliated venture studio of Alloy Therapeutics) with additional participation from Tellus BioVentures. The proceeds will be used to develop drug candidates to treat autoimmune and inflammatory disorders by developing cytokine-targeting bispecific antibodies that meaningfully improve the status quo for the millions of patients suffering from immune-mediated and autoimmune diseases..

马萨诸塞州沃尔瑟姆-（商业电线）-Cantai Therapeutics（“Cantai”）今天宣布成立并完成由代理资本和82VS（合金治疗公司的附属风险工作室）共同领导的种子融资，并获得额外参与来自Tellus BioVentures。通过开发靶向细胞因子的双特异性抗体，这些进展将用于开发治疗自身免疫性和炎性疾病的候选药物，这有意义地改善数百万患有免疫介导和自身免疫性疾病的患者的现状。。

Agent conceived the idea for Cantai’s products and partnered with 82VS to further develop the concept. Agent’s strong track record in financing companies in the autoimmune space paired with 82VS’s company creation capabilities and deep bench of expert researchers is a perfect match to join forces to develop such therapies.

代理商构思了Cantai产品的理念，并与82VS合作进一步发展这一概念。代理商在自身免疫领域为公司融资的强大记录与82VS的公司创建能力和深入的专家研究人员队伍配合，是联合开发此类疗法的完美匹配。

As part of the financing, Alloy will perform services to advance Cantai programs using Alloy’s broad suite of human antibody discovery technologies, including the ATX-CLC (Common Light Chain) mouse platform for the discovery of bispecific antibody therapeutics..

作为融资的一部分，Alloy将使用Alloy广泛的人类抗体发现技术（包括用于发现双特异性抗体疗法的ATX-CLC（普通轻链）鼠标平台）为推进Cantai计划提供服务。。

Geeta Vemuri, Ph.D., M.B.A., Founder and Managing Partner of Agent Capital, will be the Board Chair. 'We are thrilled to launch Cantai and to power it with the deep research capabilities at Alloy Therapeutics,' she noted. 'It requires a team effort to drive meaningful drug development for patients who are suffering with high unmet diseases.'.

Geeta Vemuri博士，M.B.A.，代理资本的创始人和管理合作伙伴，将担任董事会主席她指出，我们很高兴推出Cantai并通过合金治疗学的深入研究能力为其提供动力它需要团队努力为患有高度未满足疾病的患者推动有意义的药物开发。

Errik Anderson, M.B.A., General Partner at 82VS and Founder and Chief Executive Officer at Alloy, joins the Board of Directors. “Cantai is a great example of how our 82VS model allows us to build bespoke partnerships with top-tier investors like Agent Capital,” said Mr. Anderson. “We are excited to leverage Alloy’s high throughput antibody discovery engine to enable the capital efficient development of next-generation immune-modulating therapeutics for patients in need.”.

Errik Anderson，M.B.A.，82VS的一般合作伙伴以及ALYLO的创始人兼首席执行官加入董事会。安德森先生说：“Cantai是我们的82VS模型如何让我们与代理资本等高层投资者建立定制合作关系的一个很好的例子。“我们很高兴利用Alloy的高通量抗体发现引擎，为有需要的患者提供下一代免疫调节疗法的资本高效开发。”。

About Agent Capital

关于代理资本

Agent Capital is an international life sciences investment firm that supports disruptive healthcare companies focusing on novel, differentiated therapeutics and treatments that address unmet patient needs. Agent Capital aligns with scientists, entrepreneurs, and other investors to develop the next generation of healthcare innovations, leverages their industry expertise and successful track record to source premier deals, accelerate value, and drive successful exits.

代理商资本是一家国际生命科学投资公司，支持颠覆性医疗保健公司，专注于解决未满足患者需求的新型差异化治疗和治疗。代理商资本与科学家，企业家和其他投资者保持一致，开发下一代医疗保健创新，利用他们的行业专业知识和成功的记录来获得总理交易，加速价值并推动成功退出。

Their first fund invested in 15 portfolio companies, the majority of which have executed collaborations with major pharmaceutical companies and successfully raised additional capital in the private or public markets. For more information, visit www.agentcapital.com..

他们的第一笔资金投资于15家投资组合公司，其中大部分已与主要制药公司合作，并成功在私营或公共市场筹集额外资本。欲了解更多信息，请访问www.agentcapital.com。。

About 82VS

大约82VS

82VS is the affiliated venture studio of Alloy Therapeutics, empowering exceptional scientist-entrepreneurs building therapeutic drug companies leveraging Alloy’s platforms and services. 82VS supports teams from ideation through to company creation, discovery, financing, and scaling of their businesses.

82VS是合金治疗公司的附属风险工作室，授权优秀的科学家企业家利用合金的平台和服务建立治疗药物公司。82VS支持团队从构思到公司创建，发现，融资和业务规模扩展。

Aligned with the collaborative ecosystem ethos at Alloy, 82VS looks to partner and collaborate at every stage of the process including bringing in venture capital partners at the earliest stages of company creation..

与合金协作生态系统精神相一致，82VS在流程的每个阶段都寻求合作和合作，包括在公司创建的最早阶段引入风险投资合作伙伴。。

About Alloy Bispecific Discovery Services

关于合金双特异性发现服务

Alloy Therapeutics' Bispecific Discovery Service aims to democratize access to enabling platform technologies, capabilities, and expertise necessary to discover novel, developable, and therapeutically functional bispecific antibodies. At the core of this offering, Alloy has created a Common Light Chain mouse, ATX-CLC, to build bispecifics with better manufacturability and developability profiles by solving heavy and light chain pairing challenges.

Alloy Therapeutics的双特异性发现服务旨在使发现新型，可开发和治疗功能的双特异性抗体所需的支持平台技术，能力和专业知识的访问民主化。作为此产品的核心，合金通过解决重链和轻链配对挑战，创建了一种常见的轻链鼠标ATX-CLC，以构建具有更好可制造性和可开发性的双特异性产品。

Alloy has demonstrated that the ATX-CLC maintains unrestricted heavy chain diversity and immune response comparable with that of the ATX-Gx platform trusted by 150+ partners. The Common Light Chain bispecific platform is integrated with Alloy's world-class expertise in protein engineering and rapid characterization and functional screening to prioritize and deliver bispecific lead candidates that can progress rapidly towards the clinic..

合金已经证明，ATX-CLC保持不受限制的重链多样性和免疫反应，与150+合作伙伴信任的ATX Gx平台相当。常见的轻链双特异性平台与Alloy在蛋白质工程方面的世界级专业知识以及快速表征和功能筛选相结合，以优先考虑并提供可快速进入临床的双特异性候选药物。。